- Home
- Publications
- Publication Search
- Publication Details
Title
Antibody-Drug Conjugates in Cancer Therapy
Authors
Keywords
-
Journal
Annual Review of Medicine
Volume 64, Issue 1, Pages 15-29
Publisher
Annual Reviews
Online
2012-10-09
DOI
10.1146/annurev-med-050311-201823
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma
- (2012) Gerhard Moldenhauer et al. JNCI-Journal of the National Cancer Institute
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
- (2012) Hagop Kantarjian et al. LANCET ONCOLOGY
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
- (2011) A. D. Ricart CLINICAL CANCER RESEARCH
- Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2-Positive Cancer
- (2011) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- World Antibody Drug Conjugate Summit Europe
- (2011) Alain Beck et al. mAbs
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity
- (2010) J. A. Hartley et al. CANCER RESEARCH
- Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer
- (2010) A. A. N. Rose et al. CLINICAL CANCER RESEARCH
- Antibody–drug conjugates: targeted drug delivery for cancer
- (2010) Stephen C Alley et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
- (2010) Anjali Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemtuzumab Ozogamicin: One Size Does Not Fit All—The Case for Personalized Therapy
- (2010) Farhad Ravandi JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
- (2010) Howard A. Burris et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates
- (2009) Hans K. Erickson et al. BIOCONJUGATE CHEMISTRY
- A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
- (2009) Andres Forero-Torres et al. BRITISH JOURNAL OF HAEMATOLOGY
- Potent antibody drug conjugates for cancer therapy
- (2009) Peter D Senter CURRENT OPINION IN CHEMICAL BIOLOGY
- The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
- (2009) S. C. Alley et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance
- (2008) Greg M. Thurber et al. ADVANCED DRUG DELIVERY REVIEWS
- Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
- (2008) Ezogelin Oflazoglu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Antibody-Drug Conjugates for Cancer Therapy
- (2008) Paul J. Carter et al. CANCER JOURNAL
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Anti-CD30 diabody-drug conjugates with potent antitumor activity
- (2008) K. M. Kim et al. MOLECULAR CANCER THERAPEUTICS
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
- The neuroendocrine tumors of the lung, 1926-1998: some historical observations
- (2008) Darryl Carter SEMINARS IN DIAGNOSTIC PATHOLOGY
- Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
- (2007) Ravi V. J. Chari ACCOUNTS OF CHEMICAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More